Online first
Clinical vignette
Published online: 2024-11-26
Pasireotide treatment in giant prolactinoma resistant to dopamine agonists
1
, 2, 1, 1, 1, 1
, 2, 1, 1, 1, 1
Abstract
Not required for Clinical Vignette.
Keywords: pasireotidegiant prolactinomaprolactinomacabergoline
References
- Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014; 170(6): R213–R227.
- Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023; 19(12): 722–740.
- Zielinski G, Ozdarski M, Maksymowicz M, et al. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery. Front Endocrinol (Lausanne). 2020; 11: 439.
- Lasolle H, Vasiljevic A, Borson-Chazot F, et al. Pasireotide: A potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris). 2019; 80(2): 84–88.
- Coopmans EC, van Meyel SWF, Pieterman KJ, et al. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol. 2019; 181(2): K21–K27.
